---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-011161"
form_type: "8-K"
ticker: null
cik: "0001709401"
company_name: "Rubius Therapeutics, Inc."
filed_at: "2023-02-06T23:59:59+00:00"
generated_at: "2026-06-20T00:09:55.984344+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Rubius receives Nasdaq delisting notice; three directors resign, CEO extends term

## Summary
- Nasdaq notified Rubius of delisting on Feb 15, 2023 for bid price <$1.00 and public shell status; company to request hearing.
- CEO Dannielle Appelhans extends employment until March 3, 2023 (previously Jan 31); may provide consulting.
- Chief Scientific Officer Laurence Turka stepped down Jan 31, 2023; remains as consultant.
- Three directors (Cuss, Rosenblatt, Schaffert) resigned Jan 31; no disagreement with company.
- Company continues strategic review; no assurance of value realization for stockholders.

## SEC filing metadata
- accession: 0001104659-23-011161
- form_type: 8-K
- cik: 0001709401
- company_name: Rubius Therapeutics, Inc.
- filed_at: 2023-02-06T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 3.01, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1709401/000110465923011161/0001104659-23-011161-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1709401/000110465923011161/tm235566d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-011161
- JSON: https://secwatch.observer/filing/0001104659-23-011161.json
- Plain text: https://secwatch.observer/filing/0001104659-23-011161.txt

## Key facts
- Listing & Compliance Notices
  Rubius Therapeutics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5450(a)(1), 5101).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1), 5101
  source text: February 6, 2023, Rubius Therapeutics, Inc. (the “Company”) was notified by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that, based upon the Company’s non-compliance with the $1.00 bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) as of January 23, 2023, and the Staff’s determination that the Company is a “public shell” as that term is defined in Nasdaq Listing Rule 5101, the Company would be delisted at the opening of business on February 15, 2023 unless the Company timely requests a hearing before a Nasdaq Hearings Panel (the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1709401/000110465923011161/0001104659-23-011161-index.htm
- Executive change
  Michael Rosenblatt resigned as Director at Rubius Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: On January 31, 2023, Francis Cuss, M.B., B. Chir., FRCP, Michael Rosenblatt, M.D. and Susanne Schaffert, Ph.D. , each notified the Company of their respective resignations as members of the Company’s board of directors, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1709401/000110465923011161/0001104659-23-011161-index.htm
- Executive change
  Susanne Schaffert resigned as Director at Rubius Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: On January 31, 2023, Francis Cuss, M.B., B. Chir., FRCP, Michael Rosenblatt, M.D. and Susanne Schaffert, Ph.D. , each notified the Company of their respective resignations as members of the Company’s board of directors, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1709401/000110465923011161/0001104659-23-011161-index.htm
- Executive change
  Laurence Turka departed as Chief Scientific Officer at Rubius Therapeutics, Inc..
  - Action: stepped down
  - Role: Chief Scientific Officer
  source text: On January 31, 2023, Laurence Turka, M.D., stepped down from his position as Chief Scientific Officer and Head of Research and Translational Medicine of the Company on the terms previously disclosed in the November 8-K.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1709401/000110465923011161/0001104659-23-011161-index.htm
- Executive change
  Francis Cuss resigned as Director at Rubius Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: On January 31, 2023, Francis Cuss, M.B., B. Chir., FRCP, Michael Rosenblatt, M.D. and Susanne Schaffert, Ph.D. , each notified the Company of their respective resignations as members of the Company’s board of directors, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1709401/000110465923011161/0001104659-23-011161-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.